NeoGenomics, Inc.(NEO): For the most recent quarter end, NeoGenomics, Inc. reported Annual Earnings of $-0.01. Based on the filings, last years Annual Earnings was, $0.02. For the most recent quarter end, NEO reported a surprise Earnings per Share of -150% . The consensus estimate for current quarter is $0.01 and for the current fiscal year, the estimate is $0.08. For the Next fiscal year, the estimate is $0.15 based on the consensus.
NeoGenomics, Inc. has received $0.01 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 5 Financial Advisor in the Stock Trading Firms. Among 5 Analysts, Bottom line EPS Estimate for the current quarter is $0 while the top line estimate is $0.02 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -50%. NeoGenomics, Inc. results fell short with a surprise EPS of -150% or $-0.03. The Actual EPS was $-0.01 compared to the Estimated EPS of $0.02 during its most recent quarterly earnings.
NeoGenomics, Inc. has a Price to Earnings ratio of 112.86 for the trailing twelve month period. The price to book ratio of the company for the most recent quarter is 3.06. For the Most Recent Fiscal Year, NeoGenomics, Inc. has a price to cash ratio of 62.17. For the Trailing twelve month period, company showed a Net Profit Margin of -3.1% and Return on Equity of the stock is 3.56%.
NeoGenomics Last issued its quarterly earnings results on Feb 22, 2017. The company reported $0.05 EPS for the quarter, beating the analyst consensus estimate by $ 0.02. Analyst had a consensus of $0.03. The company had revenue of $60.50 million for the quarter, compared to analysts expectations of $61.50 million. The companys revenue was up 121.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.03 EPS.
Company has reported several Insider transactions to the SEC, on Sep 27, 2016, Maher Albitar (Chief Medical Officer) sold 2,800 shares at 8.40 per share price.On May 27, 2016, Oort Douglas M Van (Chairman and CEO) sold 481,387 shares at 8.72 per share price.On May 20, 2016, Steven A Ross (CIO) sold 18,000 shares at 8.50 per share price.
NeoGenomics, Inc. (NASDAQ:NEO) rose 3.67% or 0.29 points on Wednesday and made its way into the gainers of the day. After trading began at $7.92 the stock was seen hitting $8.3 as a peak level and $7.71 as the lowest level. The stock ended up at $8.19. The daily volume was measured at 753,751 shares. The 52-week high of the share price is $9.879 and the 52-week low is $5.77. The company has a market cap of $643 million.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The companys testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.